S

Sosei Group Corp
TSE:4565

Watchlist Manager
Sosei Group Corp
TSE:4565
Watchlist
Price: 1 022 JPY -1.16% Market Closed
Market Cap: 91.9B JPY
Have any thoughts about
Sosei Group Corp?
Write Note

Sosei Group Corp
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sosei Group Corp
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
S
Sosei Group Corp
TSE:4565
Cash from Operating Activities
ÂĄ2.4B
CAGR 3-Years
N/A
CAGR 5-Years
-9%
CAGR 10-Years
10%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash from Operating Activities
ÂĄ876.3B
CAGR 3-Years
-5%
CAGR 5-Years
10%
CAGR 10-Years
14%
Daiichi Sankyo Co Ltd
TSE:4568
Cash from Operating Activities
ÂĄ583.9B
CAGR 3-Years
73%
CAGR 5-Years
25%
CAGR 10-Years
17%
Otsuka Holdings Co Ltd
TSE:4578
Cash from Operating Activities
ÂĄ379.8B
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
8%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash from Operating Activities
ÂĄ409.9B
CAGR 3-Years
17%
CAGR 5-Years
21%
CAGR 10-Years
27%
Astellas Pharma Inc
TSE:4503
Cash from Operating Activities
ÂĄ200.8B
CAGR 3-Years
-15%
CAGR 5-Years
-4%
CAGR 10-Years
-1%
No Stocks Found

Sosei Group Corp
Glance View

Market Cap
91.9B JPY
Industry
Pharmaceuticals

Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 198 full-time employees. The company went IPO on 2004-07-29. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.

Intrinsic Value
1 330.98 JPY
Undervaluation 23%
Intrinsic Value
Price
S

See Also

What is Sosei Group Corp's Cash from Operating Activities?
Cash from Operating Activities
2.4B JPY

Based on the financial report for Sep 30, 2024, Sosei Group Corp's Cash from Operating Activities amounts to 2.4B JPY.

What is Sosei Group Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%

Over the last year, the Cash from Operating Activities growth was 271%.

Back to Top